Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX moved a median of 0.00% 30 minutes after news, and -0.05% by the close. How CRNX actually reacts to news — the realized, point-in-time move the market made, measured across 482 labeled events over the last three years with zero look-ahead.
CRNX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 46% | 456 |
| 30-min | 0.00% | 50% | 456 |
| 60-min | -0.10% | 44% | 456 |
| to close | -0.05% | 46% | 455 |
| Middle 50% of CRNX reactions | -0.94% to +0.81% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 482 |
Half of all Crinetics Pharmaceuticals, Inc. news events land between -0.94% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CRNX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 22 | -0.01% | 18% | -0.04% |
| Coverage initiations | 23 | -0.53% | 44% | -0.03% |
| Rating reiterations | 90 | +0.03% | 52% | +0.13% |
| Price-target raises | 24 | -0.16% | 46% | +0.32% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CRNX ranks against every other measured name →
That’s how CRNX usually reacts — get an email when it moves on news →Email me when CRNX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRNX's baseline. Nothing else.
Recent CRNX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Crinetics Pharmaceutical | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K Crinetics Pharmaceutical For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POSASR Crinetics Pharmaceutical | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Crinetics Pharmaceutical | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Crinetics Pharmaceutical For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -0.01% | |
| Form 8-K Crinetics Pharmaceutical For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -0.02% | |
| Form 8-K Crinetics Pharmaceutical For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +0.38% | |
| Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.09% | +0.15% | |
| Are ACA, CRNX, LEG Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.10% | +0.12% | |
| Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.10% | +0.12% | |
| Form 10-Q Crinetics Pharmaceutical For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.10% | +0.12% | |
| Form 8-K Crinetics Pharmaceutical For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.10% | +0.12% | |
| Form DEFM14A Crinetics Pharmaceutical | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | +0.11% | |
| Are UTZ, CRNX, SOLS Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.01% | -0.13% | |
| Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.01% | +0.01% | |
| Form PREM14A Crinetics Pharmaceutical For: Jul 21 | SEC filing · Form PREM14A | SEC EDGAR | -0.04% | -0.24% | |
| Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.02% | +0.15% | |
| Form 8-K Crinetics Pharmaceutical For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +0.01% | |
| Form DEFA14A Crinetics Pharmaceutical | SEC filing · Form DEFA14A | SEC EDGAR | -0.06% | +0.01% | |
| Are ESI, CRNX, SOLS Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.06% | -0.04% | |
| CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | GlobeNewswire | +0.00% | -0.02% | |
| CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.07% | -0.04% | |
| Form 8-K Crinetics Pharmaceutical For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | -0.04% | |
| Form DEFA14A Crinetics Pharmaceutical | SEC filing · Form DEFA14A | SEC EDGAR | -0.07% | -0.04% | |
| Vertex to Acquire Crinetics Pharmaceuticals | Press release | Business Wire | -0.07% | -0.04% | |
| Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 | Press release | GlobeNewswire | -0.32% | +3.17% | |
| Form 8-K Crinetics Pharmaceutical For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.44% | +1.24% | |
| Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 | Press release | GlobeNewswire | +0.17% | +1.56% | |
| Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control | Press release | GlobeNewswire | +0.17% | +1.56% | |
| Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities | Press release | GlobeNewswire | +0.00% | +1.63% | |
| Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations | Press release | GlobeNewswire | +0.29% | -4.48% | |
| Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 | Press release | GlobeNewswire | +0.30% | -0.59% | |
| Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -8.50% | -12.98% | |
| Form 10-Q Crinetics Pharmaceutical For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -8.50% | -12.98% | |
| Form 8-K Crinetics Pharmaceutical For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -8.50% | -12.98% | |
| Form ARS Crinetics Pharmaceutical For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.47% | +0.96% | |
| Form DEF 14A Crinetics Pharmaceutical For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.47% | +0.96% | |
| Form DEFA14A Crinetics Pharmaceutical | SEC filing · Form DEFA14A | SEC EDGAR | +0.47% | +0.96% | |
| Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults | Press release | GlobeNewswire | +0.19% | -3.20% | |
| Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer | Press release | GlobeNewswire | +0.10% | +0.51% | |
| Form 8-K Crinetics Pharmaceutical For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -1.33% | |
| Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | +0.27% | +0.13% | |
| Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly | Press release | GlobeNewswire | -0.80% | -7.19% | |
| Form 8-K Crinetics Pharmaceutical For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -1.17% | -2.58% | |
| Form 8-K Crinetics Pharmaceutical For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -2.37% | |
| Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.64% | -8.91% | |
| Form 10-K Crinetics Pharmaceutical For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.64% | -8.91% | |
| Form 8-K Crinetics Pharmaceutical For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | -8.91% | |
| Form S-8 Crinetics Pharmaceutical | SEC filing · Form S-8 | SEC EDGAR | -1.64% | -8.91% | |
| Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March | Press release | GlobeNewswire | +0.46% | -1.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRNX section they belong to.
Where else CRNX is measured.
CRNX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ResMed Inc. (RMD) | 485 | -0.08% | 44% |
| Auris Medical Holding AG (EARS) | 484 | -0.75% | 35% |
| Medtronic plc. Ordinary Shares (MDT) | 481 | -0.06% | 45% |
| Alkermes plc - Ordinary Shares (ALKS) | 480 | -0.03% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Crinetics Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled CRNX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 482 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CRNX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRNX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.